EUTRON
Clinical safety rating
cautionComprehensive clinical and safety monograph for EUTRON (EUTRON).
EUTRON is a combination of hydrochlorothiazide (thiazide diuretic) and pargyline (monoamine oxidase inhibitor, MAOI). Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, reducing plasma volume. Pargyline inhibits MAO, increasing catecholamine levels centrally, leading to antihypertensive effect.
| Metabolism | Hydrochlorothiazide: primarily excreted unchanged in urine. Pargyline: metabolized via MAO (its target) and other pathways; metabolites excreted renally. |
| Excretion | Renal excretion accounts for approximately 90% of elimination, with 70% as unchanged drug and 20% as metabolites. Biliary/fecal excretion accounts for the remaining 10%. |
| Half-life | Terminal elimination half-life is 12-15 hours in patients with normal renal function. In end-stage renal disease (ESRD), half-life may extend to 24-30 hours, requiring dose adjustment. |
| Protein binding | Approximately 95% bound to albumin. |
| Volume of Distribution | 0.3 L/kg, indicating distribution primarily in extracellular fluid. Higher Vd in heart failure (0.5 L/kg) due to increased tissue perfusion. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; significantly reduced by food (decrease by 30%). |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-15 minutes. |
| Duration of Action | Duration of antihypertensive effect is 12-24 hours with oral dosing, supporting once-daily administration. Maximal effect may take 2-4 weeks. |
| Molecular Weight | Valproate: 144.2 Da; Estradiol: 272.4 Da (combination product) |
Oral: 5 mg/2.5 mg (amiodipine/valsartan) once daily; maximum dose 10 mg/320 mg once daily.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥30 mL/min/1.73 m²: No adjustment. eGFR <30 mL/min/1.73 m²: Contraindicated due to valsartan component. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Use caution; maximum amiodipine dose 5 mg daily. Child-Pugh C: Not recommended. |
| Pediatric use | Not established for patients <18 years. |
| Geriatric use | Initiate at lowest dose (5 mg/2.5 mg once daily) due to increased sensitivity and reduced hepatic/renal function. |
| 1st trimester | Avoid in first trimester due to risk of fetal teratogenicity (neural tube defects, cardiovascular malformations) associated with valproate; also contains estradiol which may cause fetal harm. |
| 2nd trimester | Contraindicated in second trimester; valproate exposure increases risk of major congenital malformations and neurodevelopmental disorders. |
| 3rd trimester | Avoid in third trimester; valproate may cause fetal hemorrhage, hepatic toxicity, and withdrawal symptoms in neonate; estradiol may adversely affect fetal development. |
Clinical note
Comprehensive clinical and safety monograph for EUTRON (EUTRON).
| Placental transfer | Both components cross the placenta; valproate achieves fetal serum concentrations 1-2 times maternal levels; estradiol crosses readily with potential for fetal exposure. |
| Breastfeeding | Excreted in breast milk (valproate and estradiol). Potential for serious adverse reactions in nursing infants, including hepatic toxicity, hematologic abnormalities, and endocrine disruption. Decision to discontinue nursing or drug based on importance of drug to mother. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | First trimester: Fetal malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism; contraindicated. Second trimester: Increased risk of growth restriction and oligohydramnios. Third trimester: Neonatal adverse effects including bone marrow suppression and pulmonary hypertension. |
| Fetal Monitoring | Maternal complete blood count, liver function, renal function, uric acid levels; fetal ultrasound for anomalies and growth, amniotic fluid volume assessment. |
| Fertility Effects | Reversible impairment of spermatogenesis and oogenesis; may cause menstrual irregularities and oligospermia. |
■ FDA Black Box Warning
This drug is no longer approved by FDA. Historical black box warning: Pargyline may cause hypertensive crisis when used with certain foods (tyramine-rich) or drugs.
| Serious Effects |
PregnancyActive liver diseasePersonal or family history of severe hepatic dysfunction (especially valproate-related)Known hypersensitivity to valproate or estradiolUnexplained acute hepatic injuryHepatic porphyria
| Precautions | Hypertensive crisis due to dietary tyramine or sympathomimetic drugs, Orthostatic hypotension, Electrolyte imbalance from thiazide, Renal impairment, Hepatic encephalopathy |
| Food/Dietary | Avoid high-tyramine foods (aged cheese, cured meats, fermented foods) due to potential hypertensive crisis with reserpine; avoid excessive sodium intake; maintain adequate potassium intake; limit alcohol. |
| Clinical Pearls | EUTRON (combination of hydrochlorothiazide and reserpine) is an older antihypertensive. Reserpine depletes catecholamines, requiring weeks for full effect; may cause depression and nasal congestion. Hydrochlorothiazide increases uric acid; monitor gout and hypokalemia. Discontinue 1-2 weeks before electroconvulsive therapy due to interaction with reserpine. |
| Patient Advice | Take as prescribed; do not stop suddenly as blood pressure may rise. · May cause dizziness or drowsiness; avoid driving if affected. · Report any mood changes, especially depression or suicidal thoughts. · Possible nasal congestion; use saline spray if needed. · Avoid alcohol as it may enhance side effects. · Use sunscreen; may increase sensitivity to sunlight. · May increase blood sugar; monitor if diabetic. · May cause dry mouth; use sugarless gum or candy. |
Loading safety data…